Skip to content
Search
Please enter at least 3 characters.

Latest Stories

More people turning to community pharmacies as GP waiting times surge

More people turning to community pharmacies as GP waiting times surge

Sustainable funding is vital to ensure that community pharmacies can remain open and continue to provide much-needed care to patients and communities

People in the UK are increasingly relying on community pharmacies for health advice and support as they are unable to access their general practitioner (GP).


According to a recent report by the Liberal Democrats, there was a significant increase in the number of patients waiting four weeks or more to see a GP in England last year, rising from 12.8 million in 2022 to 17.6 million.

Responding to this research report, the Royal College of General Practitioners (RCGP) highlighted that GPs are also struggling to meet the increasing demand for their services due to severe staff shortages.

Dr. Victoria Tzortziou-Brown, Vice Chair of the RCGP, stated that the average number of patients each GP is responsible for has increased by 158 compared to five years ago.

Although she acknowledged that many patients are forced to wait for weeks to see their GP, she said that doctors too are grappling with “unmanageable and unsustainable workloads” and “we can’t keep doing more with less.”

There’s a growing reliance on community pharmacies for patient care amid difficulty accessing GP services.

Janet Morrison, Chief Executive of Community Pharmacy England (CPE), said: “Since the COVID-19 pandemic, people have really struggled to access their GP, with the morning rush for appointments all too familiar. They have come to rely upon community pharmacies who stayed open and accessible for health information and advice.”

The PSNC Pharmacy Advice Audit 2022 report indicated that as many as a quarter of a million people visited community pharmacies every week because they were unable to access other parts of the NHS.

Almost half of patients reported that if they did not have easy access to a pharmacy, they would have visited their GP, which would have resulted in an additional 619,000 appointments per week.

Based on these figures, the committee estimated that 32.2 million GP appointments per year could be avoided if patients had access to their local community pharmacy.

“This is why the Primary Care Recovery Plan announced the investment in the Pharmacy First service for common ailments – with the goal of freeing up 10 -12 million GP appointments a year,” Morrison said.

Launched on January 31 this year, the new scheme allows patients to get treatment and medicines from their local pharmacy for seven common conditions, including sinusitis, sore throat, earache, infected insect bite, impetigo, shingles, and uncomplicated urinary tract infections in women, without needing to see a GP.

Morrison added that they have already heard “very positive feedback” from patients about the care they’ve received and the relief of being able to access the help they need in one place.

However, she emphasised the need for sustainable underlying funding to enable the pharmacies “to stay open and continue to provide much-needed care to patients and communities.”

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less